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Edited by Laszlo NagyAbstract Non-alcoholic fatty liver disease (NAFLD) is associ-
ated with the metabolic syndrome characterized by dislipidemia
and insulin resistance. We hypothesized that ezetimibe, an inhib-
itor of NPC1L1, improves these metabolic disorders in Zucker
obese fatty rats (ZOF). Ezetimibe signiﬁcantly lowered total
cholesterol and triglycerides in ZOF with prominent reduction
in the remnant lipoprotein fraction and small dense low density
lipoprotein fraction. Moreover, lipid deposition and ﬁbrosis of
liver were decreased by ezetimibe. Interestingly, ezetimibe
improved insulin and plasma glucose response after intraperito-
neal glucose injection. Further, ezetimibe enhanced insulin
signaling in cultured hepatocytes. Our results indicate the
potential of ezetimibe in treating the metabolic syndrome and
NAFLD.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: Metabolic syndrome; Lipid metabolism; Liver
steatosis; Insulin resistance; NPC1L1; Ezetimibe1. Introduction
Dyslipidemia including hypercholesterolemia is a major risk
factor for coronary heart disease. The level of cholesterol is
tightly regulated by endogenous synthesis in the liver and die-
tary absorption/biliary reabsorption in the small intestine [1].
Niemann-Pick C1 Like 1 (NPC1L1) has been shown to play
a pivotal role in cholesterol incorporation in the enterocytes
[2–4]. Genetically engineered NPC1L1 null mouse exhibited a
signiﬁcant reduction of atherosclerosis compared to wild type
under high-fat diet [2,5]. In addition to changes in plasma lipid
levels, NPC1L1 null mouse were signiﬁcantly protected from
fatty liver formation, which occurred in wild type mouse with
high-fat diet [2,6], suggesting a potential role for NPC1L1 in
regulation of lipid metabolism in liver. Ezetimibe, a potent
inhibitor of cholesterol absorption, has been shown to inhibit
the NPC1L1-dependent cholesterol transport at the brush bor-
ders of intestines [3,7]. Ezetimibe selectively inhibits intestinal*Corresponding author.
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doi:10.1016/j.febslet.2007.11.023cholesterol absorption [8]. In humans, ezetimibe has been
shown to lower serum LDL cholesterol levels and triglycerides
(TG) [9]. Moreover, recent studies suggest its potential eﬀect
on liver steatosis [10] and insulin resistance [11] which com-
prise the metabolic syndrome (MetS). Non-alcoholic fatty liver
disease (NAFLD) including non-alcoholic steatohepatitis
(NASH) is characterized by varying degrees of progressive ste-
atosis, lobular inﬂammation and ﬁbrosis of the liver [12,13].
Recent reports suggest type 2 diabetes mellitus, obesity and
dyslipidemia often coexists with NAFLD [14]. In particular,
hyperlipidemia and insulin resistance importantly contribute
to the initiation and progression of NAFLD [15]. Recent clin-
ical studies show that NAFLD is one of the main common
liver diseases that lead to the liver cirrhosis and hepatocellular
carcinoma [13]. However, the molecular mechanisms responsi-
ble for progression of NAFLD have not been fully under-
stood. Further, intestinal cholesterol absorption is elevated in
those with type 2 diabetic patients with coronary heart diseases
[16], and low cholesterol absorption associates with fewer
recurrent cardiovascular events [17]. Zucker obese fatty
(ZOF) rat is good metabolic syndrome model [18] and has he-
patic steatosis [19]. The present study investigated the potential
eﬀect of ezetimibe on the development of NAFLD using
Zucker obese fatty (ZOF) rats fed with high-fat diet.2. Materials and methods
2.1. Cell culture and reagents
HepG2 cells were cultured in Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM) with 10% FBS. Monoclonal Abs (mAb) used in this study
were as follows: Anti-a smooth muscle actin (SMA) (from Sigma),
monoclonal anti-TGFb antibody (from Sigma), anti-IR-b (from Santa
Cruz), anti-phospho-IR-b (from Santa Cruz), anti-IRS-1 (from Santa
Cruz), anti-phospho-IRS-1 (from Santa Cruz), anti-Akt-1 (from
Santa Cruz), and anti-phospho-Akt-1 (from Santa Cruz).
2.2. Animal study
The experiments were approved by the Ethical Committee for Ani-
mal Experimentation of Tokyo Medical and Dental University. Male
Zucker fatty (fa/fa) rats (7 week of age) (Japan SLC, Inc., Shizuoka,
Japan) were housed with a regular 12-h/12-h light/dark cycle. Rats
were fed a low fat diet for 1 week, and following 4 weeks, one group
(n = 6) were fed Rodent Diet with 60 kcal% fat (soy bean
oil:lard = 1:10), protein 20 kcal%, and carbohydrate 20 kcal% (RE-
SEARCH DIETS, Inc., NJ) as high-fat diet (HF) and the other group
(n = 6) were fed HF containing 0.008% w/w ezetimibe (HF + Ez) which
was supplied by Schering-Plough K.K. The concentration of ezetimibeblished by Elsevier B.V. All rights reserved.
Fig. 1. Total serum cholesterol (T-Chol), triglyceride (TG), and free
fatty acid (FFA) in ZOF rats fed with high-fat diet (HF) or high-fat
diet with ezetimibe (HF + Ez) for 4 weeks. *P < 0.05 HF vs. HF + Ez,
**P < 0.001 HF vs. HF + Ez.
Fig. 2. Lipoprotein proﬁle by HPLC in ZOF rats fed with high-fat diet (HF,
weeks. Cholesterol (A) and triglycerides (B) content in chylomicron (CM), ver
high-density lipoprotein (HDL) were determined using enzymatic reagents. *
was further analyzed in 6 subfractions according to the particle size. *P <
analyzed in 6 subfractions according to the particle size. *P < 0.001 vs. HF.
M. Deushi et al. / FEBS Letters 581 (2007) 5664–5670 5665(2.7–6.4 mg/kg/day) was determined based on previous experiments
using rats [8,20]. Rats were free access to water and the foods until
the experiments. Some results were pooled and a subset was analyzed.
2.3. Metabolic measurement
Plasma lipoproteins were analyzed by on-line dual enzymatic meth-
od for simultaneous quantiﬁcation of cholesterol and TG by HPLC as
described previously [21].
2.4. TG secretion rate
TG secretion rate (TGSR) was measured as previously described
[22]. Brieﬂy, 500 mg/kg body weight of Triton WR-1339 (Sigma–
Aldrich) was injected via the tail vein into rats fasted for 5 h, and
triglyceride concentrations were measured in plasma samples taken
90 min after injection. The secretion rate expressed in milligrams per
minute was calculated from the increment in triglyceride concentration
per minute multiplied by the plasma volume of the rats (estimated as
3.5% of body weight in grams).
2.5. Tissue morphology
Liver samples were ﬁxed overnight in 4% paraformaldehyde for
cryo-sections, and 10% buﬀered formalin for embedding in paraﬃn.
Paraﬃn sections of livers were stained with hematoxylin and eosin.
Cryo-sections were stained with Oil red O. For the Fast green/Sirius
red staining, 5 lm sections were stained with 0.04% Fast green/0.1%
Sirius red for 15 min. Samples were dehydrated and mounted usingopen bars) or high-fat diet with ezetimibe (HF + Ez, closed bars) for 4
y low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and
P < 0.05, **P < 0.005 vs. HF. (C) Cholresterol content (Chol) in LDL
0.001 vs. HF. (D) Triglycerides content (TG) in VLDL was further
5666 M. Deushi et al. / FEBS Letters 581 (2007) 5664–5670malinol. To quantitate Sirius red intensity, the color was eluted form
the slide with 1 ml of 0.1% NaOH:absolute methanol (50:50) and the
absorbance was measured at 540 nm (kmax for Sirius red correspond-
ing to collagenous proteins).
2.6. Liver lipid analysis
The liver was rapidly removed and lipids were extracted from these
tissues (50 mg) according to methods modiﬁed from Folch et al. [23].
Brieﬂy, snap frozen liver was homogenized and extracted with chloro-
form/methanol (2:1 v/v) solution. The organic phase was dried and
resolubilized in 2-propanol containing 10% Triton X-100. Total
cholesterol levels and TG were determined by enzymatic kits as
described [24,25].
2.7. Preparation of HepG2 cells lysate
HepG2 cells were grown in 6 well plates up to 80% conﬂuence prior
to any treatment. Cells were washed with PBS and treated with ezetim-
ibe (25 lM) or DMSO in serum-free medium for 48 h, followed by the
treatment of insulin (10 nM) or PBS for 5 min. Cells were lysed and
subjected to Western blot analysis.Fig. 3. (A) Histological analysis of liver samples stained with hematoxylin + e
before (0w) and after 4 weeks with high-fat diet (4w HF) or high-fat diet with
livers of ZOF rats fed a high-fat diet (HF, gray bars) or high-fat diet with eze
open bars) were quantiﬁed as described in Section 2. *P < 0.01 vs. HF.2.8. Western blot analysis
Western blot analysis was performed using lysates prepared
from HepG2 cells and liver sample as described previously [26].
An equal amount of protein (20 lg) from each condition was sub-
jected to 10% SDS-PAGE. Immunoreactive proteins were detected
using an enhanced chemiluminescence (ECL) kit (Amersham Biosci-
ence).
2.9. Intraperitoneal glucose tolerance test (IPGTT)
ZOF rats were given an intraperitoneal glucose tolerance test
(IPGTT) (2 g/kg body weight of glucose) after 16 h of fasting.
Glucose and insulin levels were measured at 0, 30, and 120 min
using an enzymatic method (SRL Inc., Tokyo, Japan) for glucose
and an Ultra Sensitive ELISA kit (Morinaga, Kanagawa, Japan) for
insulin.
2.10. Statistical analysis
Data are expressed as mean values ± S.E.M. One-way ANOVA with
Tukey post-hoc test or two-tailed unpaired t-test was used to analyze
statistical signiﬁcance. Values are expressed as means ± S.E. with a va-
lue of P < 0.05 considered statistically signiﬁcant.osin (HE, 100·), Oil red O (200·), Sirius Red/Fast green staining (40·)
ezetimibe (4w HF + Ez). (B) Sirius Red-positive collagenous proteins in
timibe (HF + Ez, closed bars) for 4 weeks as compared to control (0w,
Fig. 4. Biochemical analysis of liver samples taken from ZOF with
high-fat diet (4w HF) or high-fat diet with ezetimibe (4w HF + Ez). (A)
Total cholesterol levels (Liver T-Chol) and (B) triglycerides (Liver TG)
were measured from lipids extracted from livers of ZOF rats fed a
high-fat diet (HF, gray bars) or high-fat diet with ezetimibe (HF + Ez,
closed bars) for 4 weeks as compared to control (0w, open bars).
*P < 0.01 vs. HF. (C) TG secretion rate (TGSR) of liver of ZOF rats
fed a high-fat diet (HF, open bars) or high-fat diet with ezetimibe
(HF + Ez, closed bars). (D) Expressions of SMA and TGFb in the liver
samples before (0w) and after 4 weeks with high-fat diet (4w HF) or
high-fat diet with Ezetimibe (4w HF + Ez). Blots represent 3 indepen-
dent sets of experiments with similar results.
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3.1. Food consumption and body weights
We monitored the food consumption and body weight of
both groups throughout the observation period. Food con-
sumption was not aﬀected by ezetimibe treatment, and both
groups continuously gained weight. Finally, the mean body
weight was not signiﬁcantly changed in both groups (data
not shown).
3.2. Ezetimibe improves HF-induced dyslipidemia in ZOF
We measured plasma lipid and lipoprotein proﬁles of both
groups after 4 weeks of HF diet. HF diet induced hyperlipid-
emia characterized by elevated serum cholesterol level. Ezetim-
ibe treatment reduced plasma cholesterol, TG, and free fatty
acid (FFA) by 27%, 32%, and 31%, respectively (Fig. 1) and
signiﬁcantly decreased cholesterol in VLDL and LDL frac-
tions (Fig. 2A). Decrease in TG content was prominent for
chylomicron and VLDL fractions (Fig. 2B). As shown in
Fig. 2C, reduction of cholesterol was attributed to smaller size
particles, Fr12 and Fr13 (the average diameters are 18.6 nm
and 16.7 nm, respectively), which correspond to small dense
LDL. In contrast, reduction of TG was prominent in larger
size particles, Fr4 and Fr5 (the average diameters are
53.6 nm and 44.5 nm, respectively), which correspond to
VLDL1 (Fig. 2D).
3.3. Ezetimibe improves HF-induced hepatic steatosis and
ﬁbrosis in ZOF
We examined whether ezetimibe aﬀects HF-induced steatosis
in ZOF. Liver histology showed that HF diet induced lipid
accumulation in the liver determined by Oil Red O staining,
though we did not ﬁnd signiﬁcant inﬁltration of inﬂammatory
cells by HE staining (HE and Oil Red O in Fig. 3A). Ezetimibe
treatment improved HF-induced hepatic ﬁbrosis of ZOF
judged from Sirius Red staining (Sirius Red in Fig. 3A) and
its quantity (Fig. 3B). In fact, ezetimibe treatment improved
HF increased hepatic cholesterol and TG content (Fig. 4A
and B). Interestingly, there was no signiﬁcant diﬀerence in
TG secretion rate between ezetimibe treated and control
groups (Fig. 4C). Further, immunoblotting showed increased
expressions of SMA and TGFb in the liver by HF diet
(Fig. 4D). Taken together, ZOF rats had liver steatosis, which
did not reach to cirrhosis, and ezetimibe could inhibit progres-
sion of liver steatosis.
3.4. Ezetimibe improves HF-induced insulin resistance in ZOF
Hepatic steatosis as well as hyperlipidemia closely associates
with insulin resistance. Since NPC1L1 is expressed in liver as
well as intestine in humans, we examined whether ezetimibe af-
fects glycemic metabolism in the liver [2]. When IPGTT was
carried out in ZOF, serum glucose level was strongly peaked
at 30 min and gradually decreased at 120 min after glucose
loading in HF-fed ZOF as shown in Fig. 5A. In contrast, eze-
timibe treatment signiﬁcantly reduced peak glucose level at
30 min as well as that at 120 min, though fasting glucose level
was not signiﬁcantly diﬀerent from control. When insulin lev-
els were measured, its fasting level in HF diet with ezetimibe
treatment group was lower than without ezetimibe treatment
group, though not statistically signiﬁcant. The glucose-induced
insulin secretion was signiﬁcantly decreased in ezetimibe treat-ment group at 30 min and 120 min after glucose loading
(Fig. 5B). These results indicate that ezetimibe improves insu-
lin resistance of ZOF rats.
To further investigate an eﬀect of ezetimibe on insulin signal-
ing, phosphorylation of insulin receptor-b (IR-b), insulin
receptor substrate-1(IRS-1), and Akt-1 was measured in
HepG2 cells. Ezetimibe treatment augmented insulin-in-
duced-phosphorylation of IR-b, IRS-1, and Akt-1 (Fig. 5C),
suggesting its direct eﬀect on insulin resistance in hepatocytes.4. Discussion
In the present study, we demonstrated favorable eﬀects of
ezetimibe on liver steatosis and ﬁbrotic change in addition to
lipid proﬁle in ZOF rats fed with high-fat diet. Feeding high-
fat diet to ZOF rats led to obesity accompanied by hypercho-
lesterolemia, hypertriglyceridemia, fasting hyperglycemia, and
hyperinsulinemia, which are characteristic of the proﬁle often
observed in patients with MetS. Ezetimibe reduced TG and
FFA as well as cholesterol in ZOF rats without aﬀecting food
consumption. HPLC analysis revealed that ezetimibe treat-
ment lowered preferentially VLDL fraction that corresponds
to VLDL1 sub fraction (Sf 60–400) in humans [27], that re-
ﬂects a signiﬁcant reduction in plasma TG. Though the precise
mechanisms are yet to be elucidated, we speculated that reduc-
tion of chylomicron synthesis in enterocytes may account for
its eﬀect in TG improvement [28]. Moreover, Davis et al.
Fig. 5. (A) Glucose responses to IPGTT after ezetimibe treatment in ZOF. Ezetimibe treatment (HF + Ez) signiﬁcantly improved glucose. *P < 0.05
vs. HF. (B) Insulin responses to IPGTT after ezetimibe treatment in ZOF. Ezetimibe treatment (HF + Ez) signiﬁcantly improved insulin. *P < 0.05
vs. HF, **P < 0.01 vs. HF. (C) Eﬀects of ezetimibe on insulin-induced-phosphorylation of IR-b, IRS-1 and Akt in HepG2 cells. HepG2 cells were
incubated with or without ezetimibe (25 lM) for 48 h followed by stimulation with insulin (10 nM) for 5 min. Immunoblotting analysis was
performed as described in methods. *P < 0.05 vs. HF, **P < 0.01 vs. HF. AU, arbitrary units.
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reduced 80–90% in NPC1L1/apoE-double deﬁcient mice rela-
tive to apoE-deﬁcient mice [5]. Future experiments will require
to elucidate the eﬀect of ezetimibe in TG-rich lipoprotein
metabolism. Large VLDL1 particles are converted to athero-
genic small dense LDL (sdLDL) particles by cholesteryl ester
transport protein (CETP) and hepatic lipase (HL), which are
commonly increased in type 2 diabetes [29]. Indeed, ezetimibe
treatment lowered LDL subfractions 12 and 13, which suggests
the favorable eﬀect of the compound on artherogenic lipid pro-
ﬁle.
Interestingly, ezetimibe also improved HF-induced hepatic
steatosis or lipid accumulation in addition to systemic dyslipi-
demia. Fat content of the liver reﬂects the balance between
FFA ﬂux, fatty acid oxidation, de novo lipogenesis and VLDL
secretion. Taking into consideration its primary eﬀect, ezetim-ibe seemed to ameliorate liver steatosis by decreasing lipid
absorption and subsequently decreased lipoprotein synthesis.
On the other hand, lipid secretion from the liver determined
by the TGSR was not aﬀected by ezetimibe treatment. This
ﬁnding indicates that ezetimibe may aﬀect clearance or uptake
but not secretion of triglyceride [30]. HF also induced mild
ﬁbrotic changes in the liver, which were inhibited by ezetimibe
treatment. In chronic liver diseases, TGFb plays a pivotal role
in the progression of hepatic ﬁbrosis. TGFb produced from
Kupﬀer cell and inﬂammatory cells activates hepatic satellite
cell (HSC). In fact, Ezetimibe abolished upregulation of TGFb
further suggesting its protective role against liver steatosis.
Unlike mouse NPC1L1 protein, which is predominantly
expressed in intestine, human and rat NPC1L1 is abundantly
expressed in liver [2]. Thus contribution of NPC1L1 protein,
expressed in the liver, to the formation of steatosis can be
M. Deushi et al. / FEBS Letters 581 (2007) 5664–5670 5669postulated. It requires further investigation as to whether the
eﬀect of ezetimibe on liver steatosis and the subsequent inﬂam-
matory burden is dependent on lipid-lowering or the direct ef-
fect ezetimibe has on hepatocytes.
We also found that ezetimibe ameliorated insulin resistance
in ZOF rats. Although ezetimibe did not signiﬁcantly change
fasting glucose, IPGTT data strongly indicate that ezetimibe
improved insulin sensitivity. As reported, the expression level
of NPC1L1 is higher in liver compared to other insulin-sensi-
tive organs such as muscle and adipose tissue [2]. Therefore we
hypothesized that ezetimibe could directly aﬀect insulin signal-
ing in liver, and showed that ezetimibe dramatically enhanced
insulin signaling (i.e., phosphorylation of IR, IRS-1, and Akt-
1) in HepG2 cells in vitro (Fig. 5C). Insulin resistance increases
TG lipolysis and FFA release from adipocytes, which in turn
augment insulin resistance. Boden et al. reported that FFA
not only induces insulin resistance but also activates the proin-
ﬂammatory NF-jB pathway in rat liver, resulting in the devel-
opment of steatohepatitis [31]. Hyperinsulinemia and high
glucose resulting from insulin resistance also independently
accelerate the progression of hepatic steatosis through de novo
lipogenesis [10,32]. Thus, the break down of this vicious circle
by ezetimibe may also contribute to inhibition of hepatic stea-
tosis. Further investigation will be need to elucidate the eﬀect
of ezetimibe on hepatic insulin signaling.
The limitation of our study is that we used ZOF rats fed with
high-fat diets for the model of NAFLD with MetS. Since Lep-
tin-dependent pathway plays a role in liver ﬁbrosis and insulin
sensitivity, our ﬁndings could be tested in a diﬀerent animal
model with intact leptin-dependent pathway. Though Gon-
za´lez-Ortiz et al. reported that ezetimibe treatment did not
aﬀect insulin sensitivity in obese subjects with dyslipidemia
[11,33], these subjects are not diabetic and their plasma levels
of FFA and insulin are not described. Therefore further study
will be necessary to critically access the eﬀect of ezetimibe on
insulin sensitivity in NAFLD with MetS.
In conclusion, ezetimibe treatment improved hepatic steato-
sis via both NPC1L1 pathway and recovery of insulin resis-
tance, as well as dyslipidemia in ZOF rats. This indicates
that ezetimibe can be an eﬀective therapy for ameliorating
NAFLD with MetS. Large-scale clinical trials will provide us
with more deﬁnite answer as to whether ezetimibe treatment
can improve fatty liver, and resultantly reduce the risk of pro-
gression of liver diseases in patients with the MetS.
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